Pi Healthcare Signs Exclusive Distribution Agreement with Neteera, Outpacing Major Conglomerates

Medical artificial intelligence (AI) and digital healthcare company Pi Healthcare Co., Ltd. (CEO Lee Young-gyou) announced on the 10th that it has signed a Korean exclusive master distribution agreement with Neteera Technologies Ltd., an Israeli global non-contact radar sensing technology company, and is formally launching its entry into the domestic non-contact biosignal monitoring market.

This agreement holds significant meaning in that Pi Healthcare was selected as the final exclusive partner in a partner selection process that competed among major domestic conglomerates and KOSDAQ-listed healthcare companies.

Pi Healthcare was recognized for its competitive advantage not only in its own medical AI technology but also in its end-to-end business commercialization capabilities spanning medical device research and development (R&D;), clinical validation, regulatory approval, and commercialization to medical institution supply.

In particular, regulatory response capabilities necessary for global medical device technology to enter the domestic market and practical implementation capabilities to supply products to actual medical facilities served as key strengths of this partnership.

Pi Healthcare has been advancing the development and commercialization of medical image analysis technology through its own medical AI solution 'DOCTOR EYE.' The flagship solution, DOCTOR EYE X-EYE, is medical AI software that assists in the diagnosis of four major fundus diseases including diabetic retinopathy, macular degeneration, glaucoma, and epiretinal membrane, and has obtained approval from the Ministry of Food and Drug Safety.

Through this process, Pi Healthcare is expanding areas of collaboration with global medical device companies based on accumulated AI software development capabilities, clinical and regulatory approval experience, and medical institution networks.

Through this agreement, Pi Healthcare has secured exclusive domestic supply rights to Neteera's 122GHz ultra-high-frequency radar-based non-contact biosignal sensing solution. This technology measures biosignals such as heart rate and respiration without directly attaching sensors to the body, and is characterized by the ability to continuously observe biosignals while reducing physical burden on patients.

It is expected to have potential applications in patient monitoring within hospitals, elderly care, care facilities, and various digital healthcare environments.

Pi Healthcare plans to combine its existing medical AI software development capabilities with its medical device import business license and domestic distribution capabilities to establish a supply system for Neteera products in Korea.

In addition to the development and commercialization of AI solutions, the goal is to expand domestic supply business of global medical device hardware to secure new revenue sources from product supply and establish a stable recurring revenue base. To this end, the company plans to gradually expand supply channels from tertiary hospitals and general hospitals to clinics and private practices, as well as care facilities and senior care markets.

In the medium to long term, the company also plans to examine the expansion of digital healthcare business by linking fundus image-based disease risk screening AI with non-contact biosignal monitoring technology. While DOCTOR EYE supports disease risk screening at specific time points through fundus image analysis, Neteera's radar sensing technology supports continuous observation of biosignals such as heart rate and respiration. Based on the complementary characteristics of the two technologies, Pi Healthcare plans to explore integrated monitoring solutions and new clinical application models in the future.

CEO Lee Young-gyou of Pi Healthcare stated, "This Korean exclusive master distribution agreement is an achievement that comprehensively recognized Pi Healthcare's medical AI technology and clinical, regulatory approval, and commercialization capabilities amid competition with major domestic conglomerates and listed companies." He added, "Based on experience developing medical AI solutions and applying them in actual clinical settings, we will successfully introduce Neteera's innovative non-contact sensing technology domestically."

He continued, "Taking this agreement as an opportunity, we will upgrade our existing AI software-focused business structure and expand new revenue bases through global advanced medical device supply. Ultimately, we aim to grow into an integrated digital healthcare company encompassing medical AI and non-contact biosignal monitoring technology."